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Abstract
 
CD1d-restricted natural killer (NK)T cells are known to potently secrete T helper (Th)1 and
Th2 cytokines and to mediate cytolysis, but it is unclear how these contrasting functional activ-
ities are regulated. Using lipid antigen–loaded CD1d tetramers, we have distinguished two sub-
sets of CD1d-restricted T cells in fresh peripheral blood that differ in cytokine production and
cytotoxic activation. One subset, which was CD4
 
 
 
, selectively produced the Th1 cytokines in-
terferon 
 
 
 
 and tumor necrosis factor 
 
 
 
, and expressed NKG2d, a marker associated with cytol-
ysis of microbially infected and neoplastic cells. This subset up-regulated perforin after expo-
sure to interleukin (IL)-2 or IL-12. In contrast, CD4
 
 
 
 CD1d-restricted NKT cells potently
produced both Th1 and Th2 cytokines, up-regulated perforin in response to stimulation by
phorbol myristate acetate and ionomycin but not IL-2 or IL-12, and could be induced to ex-
press CD95L. Further, for both CD1d-restricted NKT cell subsets, we found that antigenic
stimulation induced cytokine production but not perforin expression, whereas exposure to in-
flammatory factors enhanced perforin expression but did not stimulate cytokine production.
These results show that the various activities of CD1d-restricted T cells in tumor rejection, au-
toimmune disease, and microbial infections could result from activation of functionally distinct
subsets, and that inflammatory and antigenic stimuli may influence different effector functions.
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Introduction
 
CD1 glycoproteins comprise a family of antigen-presenting
molecules that present lipid and glycolipid antigens to T
cells (1). Five CD1 isoforms have been identified (CD1a, b,
c, d, and e), all of which are present in humans, while mice
and rats possess only CD1d (1). CD1d-restricted T cells
have been identified in both mice and humans, and have
drawn attention for their unusual ability to secrete both
Th1 and Th2 cytokines rapidly upon stimulation (2–4).
CD1d-restricted T cells were first characterized in the
mouse and were found to express a highly restricted TCR
repertoire - an invariantly rearranged V
 
 
 
14/J
 
 
 
281 TCR 
 
 
 
chain paired mainly with V
 
 
 
8
 
 
 
 TCR 
 
 
 
 chains (5, 6). Sub-
sequently, other murine CD1d-restricted T cells expressing
a variety of TCR 
 
 
 
 and 
 
 
 
 chains with diverse junctional
rearrangements were also identified (7–10). Human CD1d-
restricted T cells have been cloned that have a canonical
V
 
 
 
24/J
 
 
 
Q TCR
 
  
 
 chain that is homologous to the mu-
rine V
 
 
 
14
 
 
 
 TCR 
 
 
 
 chain, and is paired with V
 
 
 
11
 
 
 
 TCR
 
 
 
 chains (11). Human bone marrow T cells that recognize
CD1d and utilize other TCR 
 
 
 
 and 
 
 
 
 chains have also re-
cently been described (12). Murine CD1d-restricted T cells
were initially characterized as comprising the small subset
of T cells that coexpress the NK1.1 antigen (now called
CD161), a marker found on all NK cells, and were there-
fore called “NKT” cells (2). However, recent studies have
demonstrated that not all CD1d-restricted T cells are
CD161
 
 
 
 (13, 14), and that CD161 can be expressed by a
very large number of MHC class I and class II–restricted T
cells after lymphokine activation or viral infection (15–17).
Hence, CD1d-restricted T cells and CD161
 
 
 
 NKT cells
are overlapping but not identical T cell subpopulations.
The natural antigens recognized by CD1d-restricted T
cells are largely unidentified. Many CD1d-restricted T cells
appear to respond to self-antigens presented by CD1d mol-
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ecules, and some may react to microbial lipids (9, 18, 19).
Additionally, most murine V
 
 
 
14
 
 
 
 and human V
 
 
 
24
 
 
 
CD1d-restricted T cells have been found to respond
strongly to CD1d-mediated presentation of 
 
 
 
-galactosyl-
ceramide (
 
 
 
-GalCer)
 
*
 
, an unusual glycosphingolipid derived
from a marine sponge (20, 21). This lipid is not a physio-
logical antigen, but appears to be an unusual cross-reactive
molecule that is recognized by a large number of CD1d-
restricted T cells that otherwise have distinct antigenic
specificities (18). CD1d-restricted T cells with diversely re-
arranged TCRs can also recognize self-antigens presented
by CD1d, but the clones that have been tested thus far do
not respond to 
 
 
 
-GalCer, suggesting they may have differ-
ent antigenic specificities than TCR 
 
 
 
-invariant CD1d-
restricted T cells (9, 18).
CD1d-restricted T cells are associated with prevention of
type I diabetes and other autoimmune diseases (22–24), are
required for rejection of certain tumors (25, 26), and may
participate in immune responses to certain microbial infec-
tions (19, 27). These effects of CD1d-restricted T cells in
vivo appear to entail secretion of either Th1 or Th2 cyto-
kines, and may involve cytolysis. For example, in type I dia-
betes the protective effect of CD1d-restricted T cells corre-
lates with their secretion of IL-4 and/or IL-10 (22, 28, 29).
In contrast, activation of CD1d-restricted T cells by ad-
ministration of the 
 
 
 
-GalCer antigen results in heightened
IFN-
 
 
 
 production, and has a beneficial effect on several
microbial infections (30–32). In tumor rejection it is un-
clear whether CD1d-restricted T cells function primarily to
secrete IFN-
 
 
 
, which then activates cytolytic antitumor ef-
fectors such as NK cells, 
 
  
 
 T cells, or CTLs, or whether
CD1d-restricted T cells themselves carry out the cytotoxic
functions that eliminate the tumor cells (25, 33, 34). Thus,
it seems likely that the important functions of CD1d-
restricted T cells in vivo involve secretion of Th1 or Th2
cytokines, or cell killing. However, how these distinct ef-
fector functions of CD1d-restricted T cells are regulated,
and what physiological stimuli activate their different re-
sponses, remain unknown.
Recently, a novel technique has been developed that
uses soluble antigen presenting molecules, loaded with a
specific antigen and complexed into a fluorescently labeled
tetrameric form (“tetramers”), to detect and characterize
antigen-specific T cells (35). This approach is particularly
powerful because it permits characterization of antigen-
specific T cells from fresh peripheral blood or tissue, with-
out requiring culture in vitro, and therefore allows an ex-
cellent assessment of their properties in vivo. In this study,
we use 
 
 
 
-GalCer loaded CD1d tetramers to evaluate the
functions and responses to different physiological stimuli of
fresh CD1d-restricted T cells from human peripheral
blood. Surprisingly, we find evidence of at least two func-
tionally distinct subsets of 
 
 
 
-GalCer-reactive CD1d-
restricted T cells. Furthermore, antigenic and cytokine-
mediated stimulation had different effects on the functional
 
states of CD1d-restricted T cells. These findings clarify
how CD1d-restricted T cells could render distinct Th1 and
Th2 responses, provide insight into the potential role of
CD1d-restricted T cells in IL-12–dependent tumor rejec-
tion, and suggest CD1d-restricted T cells may have cyto-
toxic functions in microbial infections that have not previ-
ously been appreciated.
 
Materials and Methods
 
Generation and Purification of the Human CD1d-Fc Fusion Pro-
tein.
 
The human CD1d-Fc fusion protein was constructed, pro-
duced, and purified as described previously for a similar murine
CD1d-Fc fusion protein (18). Briefly, a single chain construct
was designed encoding human 
 
 
 
2
 
m, a glycine-serine (gly-ser)
spacer peptide, the coding region of human CD1d truncated im-
mediately before the transmembrane domain, another gly-ser
spacer peptide, and the hinge region and Fc portions of murine
IgG
 
2a
 
. Synthetic oligonucleotide PCR primers for PCR amplifi-
cation of the truncated human CD1d fragment were obtained
from Operon Technologies. The 5
 
 
 
 primer oligonucleotide
sequence was 5
 
 
 
-GCGCGGACTAGTGCTGAAGTCCCGCA-
AAGGCTTTTC-3
 
 
 
, and the 3
 
 
 
 primer sequence was 5
 
 
 
-
GGAAGAGCGGCCGCTCCAGTAGAGGATGATGTCCTG -
GCC-3
 
 
 
. The human 
 
 
 
2
 
m
 
 
 
linker, and linker
 
 
 
Fc cDNA frag-
ments were PCR amplified and subcloned together with the
CD1d fragment as described previously (18). The resulting con-
struct was fully sequenced to ensure that no coding mutations
were present, subcloned into the pBJ1-neo expression vector
(36), and transfected into Chinese hamster ovary cells and grown
as described previously (18). Dimeric fusion protein was purified
from culture supernatants by protein A column chromatography
followed by acid elution, then further purified by size exclusion
chromatography on a Superose 6 column (Amersham Pharmacia
Biotech), and concentrated by ultrafiltration in the presence of
0.5 mg/ml OVA.
 
Preparation of the 
 
 
 
-GalCer Lipid Antigen.
 
 
 
-GalCer was syn-
thesized as described previously (37). The lyophilized lipid was
dissolved in DMSO at a concentration of 100 
 
 
 
g/ml by incuba-
tion for at least 12 h at 37
 
 
 
C with agitation, then stored at –20
 
 
 
C.
Prior to use the antigen was thawed at room temperature, then
sonicated for 10 min at 37
 
 
 
C.
 
Tetrameric Complexing and Antigen Loading.
 
Tetrameric com-
plexes of the CD1d–Fc fusion protein or the IgG
 
2a
 
 isotype
UPC10 negative control mAb (Sigma-Aldrich) were formed us-
ing fluorescently labeled protein A molecules. Protein A mole-
cules spontaneously associate in solution at neutral pH with im-
munoglobulin Fc regions, forming stable complexes containing 4
Fc molecules and 2 protein A molecules, or 1 Fc molecule and
1 protein A molecule (38). The CD1d-Fc fusion protein or
UPC10 mAb were incubated overnight at 37
 
 
 
C with Alexa 488
dye labeled protein A (Molecular Probes). Tetrameric complexes
were purified by size exclusion chromatography on a Pharmacia
Superose 6 column, and concentrated by ultrafiltration in the
presence of 0.5 mg/ml OVA. Similar nonfluorescent complexes
for use as a flow cytometry blocking reagent were prepared using
the UPC10 mAb and unlabeled protein A (Sigma-Aldrich). To
load the fusion protein with antigen, a 40:1 molar ratio of 
 
 
 
-Gal-
Cer dissolved in DMSO was incubated with the CD1d tetramer
for 24 to 48 h at 37
 
 
 
C.
 
Purification and Stimulation of Human PBMC Samples.
 
Hu-
man venous blood samples were drawn from healthy volunteer
 
*
 
Abbreviations used in this paper:
 
 
 
 
 
-GalCer, 
 
 
 
-galactosylceramide; CLA,
cutaneous lymphocyte antigen. 
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donors. PBMCs were purified by ficoll density gradient cen-
trifugation (Amersham Pharmacia Biotech). For most analyses,
to reduce nonspecific staining, B cells were removed by CD19
magnetic bead depletion using the MACS
 
®
 
 system, according
to the manufacturer’s protocol (Miltenyi Biotec). For analyses
of NKG2d expression, CD4
 
 
 
 cells were also removed from a
portion of each sample by CD4 magnetic bead depletion using
the MACS
 
®
 
 system. For stimulation experiments, freshly puri-
fied B cell depleted PBMCs were transferred into culture me-
dium (RPMI supplemented with 
 
L
 
-glutamine and penicillin/
streptomycin, Life Technologies, and 10% bovine calf serum,
Hyclone Laboratories) containing a final concentration of 1
 
 
 
g/ml 
 
 
 
-GalCer, 20 nM IL-2 (Chiron Corp.), 20 ng/ml IL-
12 (Peprotech), or 1 
 
 
 
g/ml purified LPS (Sigma-Aldrich) in
the presence or absence of monensin (BD PharMingen) as
specified, and incubated for 12–14 h at 37
 
 
 
C and 5% CO
 
2
 
. For
samples that were incubated overnight without monensin, the
incubation was continued for an additional 4 h in the presence
of monensin to allow intracellular proteins to accumulate.
PMA/ionomycin stimulation was performed for 6 h at 37
 
 
 
C
and 5% CO
 
2
 
 in culture medium containing 25 ng/ml PMA
(Sigma-Aldrich), 1 
 
 
 
g/ml ionomycin (Sigma-Aldrich), and
monensin. Unstimulated control samples were incubated
overnight in culture medium containing monensin at 37
 
 
 
C
and 5% CO
 
2
 
.
 
Flow Cytometric Staining and Analysis.
 
Each analysis was per-
formed on PBMC samples from at least three different donors.
PBMC samples were blocked with a solution containing 100
 
 
 
g/ml nonfluorescent UPC10 tetramer, 50 
 
 
 
g/ml MOPC21
IgG1 mAb (Sigma-Aldrich), 0.5 mg/ml OVA, and 0.05% NaN
 
3
 
.
Staining and analysis were performed in FACS
 
®
 
 buffer contain-
ing 1 mg/ml BSA in PBS and 0.05% NaN
 
3
 
. For analysis of cell
surface markers, the samples were stained with the 
 
 
 
-GalCer–
loaded CD1d tetramer, DMSO mock-treated CD1d tetramer, or
the UPC10 negative control tetramer, each diluted to 30 
 
 
 
g/ml
in FACS
 
®
 
 buffer, and phycoerythrin (PE)-or cychrome (Cy)-
conjugated antibodies against the following markers, as specified:
CD3-Cy, CD4-Cy, CD8
 
 
 
-Cy, CD161-PE, CD94-PE, CD69-
PE, CD62L-PE, CXCR3-PE, CCR5-PE, CD103-PE, mIgG
 
1
 
-
PE negative control, mIgG
 
2a
 
-PE negative control, (all from
BD PharMingen); CD8
 
 
 
-PE (Beckman Coulter); 
 
 
 
4
 
 
 
7 (ACT1
mAb, provided by Millenium Pharmaceuticals) conjugated to
pyridyldisulfide derivatized R-PE (Molecular Probes). Analysis
of cutaneous lymphocyte antigen (CLA) expression was per-
formed using unconjugated anti-CLA followed by mouse anti–
rat IgM-PE (both from BD PharMingen). CCR7 expression was
evaluated using an anti-CCR7 mAb (clone 2H4, provided by
Millenium Pharmaceuticals) followed by rat anti–mouse IgM-PE
(Jackson ImmunoResearch Laboratories). Staining for NKG2d
was performed using the 
 
 
 
-GalCer loaded or DMSO mock-
treated CD1d tetramer and the 1D11 mAb (provided by Thomas
Spies), or a negative control mAb, followed by anti–Ig
 
 
 
-PE (BD
PharMingen).
For intracellular staining the samples were blocked as described
above, then stained with the 
 
 
 
-GalCer loaded or DMSO mock-
treated CD1d tetramer and anti–CD3-Cy or anti-CD4-Cy, then
fixed and permeabilized according to the manufacturer’s protocol
(BD PharMingen), and then stained using the following PE-con-
jugated antibodies: anti–IFN-
 
 
 
, anti–TNF-
 
 
 
, anti-GM–CSF,
anti–IL-2, anti–IL-4, anti–IL-5, anti–IL-6, anti–IL-10, anti–IL-
13, anti-perforin; or mIgG
 
1
 
, mIgG
 
2a
 
, rIgG
 
1
 
, rIgG
 
2a
 
, mIgG
 
2b
 
 nega-
tive control antibodies (BD PharMingen); or anti-CD95L–PE
from Caltag Laboratories.
 
Flow cytometric data collection was performed on a Becton
Dickinson FACScan™, and at least 50–200,000 events were
collected for each sample to ensure a sufficient number of tet-
ramer positive events for analysis. Data analysis was performed
using Flowjo flow cytometry software (Treestar, Inc.). Samples
were gated on lymphocytes using forward and side scatter pa-
rameters. Positive staining for each maker was determined by
comparison to appropriate isotype-matched negative controls
and unstimulated samples.
 
Results and Discussion
 
Flow Cytometric Staining Using CD1d Tetramers.
 
To in-
vestigate the functions of fresh peripheral blood CD1d-
restricted T cells, we used tetrameric complexes of a human
CD1d-Fc fusion protein, or the isotype-matched negative
control UPC10 mAb, and fluorescently tagged protein A
in flow cytometric analyses. To verify its specificity, the
CD1d tetramer was tested for staining of two hu-
man CD1d-restricted NKT cell clones, DN2.B9 and
DN1.10B3, that respond functionally to 
 
 
 
-GalCer (21).
The CD1d tetramer was preincubated with 
 
 
 
-GalCer dis-
solved in DMSO, or with an equivalent volume of
DMSO alone. Clearly positive staining of NKT clones
DN1.10B3 and DN2.B9 was observed using the CD1d
tetramer preincubated with 
 
 
 
-GalCer (MFI
 
   
 
67.3 and
86.2, respectively), while staining by the CD1d tetramer
that was mock-treated with DMSO (MFI
 
   
 
3.2 and 3.03),
was equivalent to that of the UPC10 negative control
complex (MFI 
 
 
 
 3.03 and 3.04). Thus, addition of a lipid
antigen was required for CD1d tetramer binding to the
NKT cell clones. Three 
 
  
 
 T cell clones and one 
 
  
 
 T
cell clone that were not CD1d-restricted were stained by
neither the 
 
 
 
-GalCer antigen treated, nor the DMSO
mock-treated CD1d tetramer (data not shown), suggesting
the CD1d tetramer staining was specific for CD1d-restricted
T cells.
We next used two-color flow cytometric analysis on
PBMC samples purified from 20 healthy donors to assess
the staining of peripheral blood T cells with the 
 
 
 
-GalCer–
loaded CD1d tetramer. The samples were stained with an
anti-CD3 mAb and the CD1d tetramer treated with
 
 
 
-GalCer, or DMSO, or with the UPC10 negative con-
trol complex. A small population of T cells that stained
positively with the 
 
 
 
-GalCer–treated tetramer could be de-
tected for 15 out of 20 donors, whereas staining with the
DMSO mock-treated CD1d tetramer was equivalent to the
UPC10 negative control complex (Fig. 1 a and b, and data
not shown). For 5 out of 20 donors, the percentage of T
cells stained by the 
 
 
 
-GalCer–treated CD1d tetramer was
not greater than the negative control staining (data not
shown). The percentage of the total T cells that were spe-
cifically stained with the tetramer ranged from undetectable
(
 
 
 
0.01% of the CD3
 
 
 
 lymphocytes) to 2.34%, with a me-
dian of 0.034% and a mean of 0.194%. Thus, in most
healthy donors a small subpopulation of peripheral blood T
cells could be detected using 
 
 
 
-GalCer–loaded CD1d
tetramers. The frequencies of 
 
 
 
-GalCer reactive CD1d- 
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restricted T cells observed in our analysis are similar to
those obtained by Karadimitris et al. who used human
CD1d tetramers loaded with 
 
 
 
-GalCer to analyze PBMC
samples from seven hepatitis C virus–infected patients and
three healthy donors (39). Two reports have suggested that
some NK cells may recognize CD1 molecules (40, 41).
However, we observed no CD1d-specific staining of
CD3
 
 
 
 lymphocytes (see Fig. 1 a and b).
We confirmed that the CD1d tetramer staining of hu-
man peripheral blood lymphocytes was specific for CD1d-
restricted T cells by deriving T cell clones from the stained
population. 14 T cell clones were established from four do-
nors by flow cytometric sorting of tetramer positive cells.
Flow cytometric analysis of the clones revealed uniform
positive staining using the 
 
 
 
-GalCer–loaded CD1d tet-
ramer and no staining using the DMSO-treated CD1d tet-
ramer or the negative control UPC10 complex (data not
shown). The clones also secreted cytokines (including IFN-
 
 
 
,
IL-4, and GM-CSF) in response to CD1d-transfectants in
the presence of 
 
 
 
-GalCer, but did not respond to 
 
 
 
-Gal-
Cer–treated untransfected parent cells (unpublished data).
Thus, human peripheral blood T cells stained by the
 
 
 
-GalCer loaded tetramer are CD1d specific and recognize
the 
 
 
 
-GalCer lipid antigen.
 
Phenotypic Characterization of CD1d Tetramer Positive
Cells.
 
Murine 
 
 
 
-GalCer–specific CD1d-restricted T cells
have been shown to be CD4
 
 
 
 or CD4 and CD8 double
negative, and to include CD161
 
 
 
 and CD161
 
 
 
 cells (13,
14). We investigated CD4, CD8
 
 
 
, and CD8
 
 
 
 staining for
CD1d tetramer positive T cells from human peripheral
blood of four healthy donors. An anti-CD4 mAb stained
approximately half of the tetramer positive cells (mean 
 
 
 
51 
 
 
 
 19%, and see Fig. 1 c). Approximately half of the tet-
ramer positive cells stained positively for CD8
 
 
 
 (mean
 
  
 
51 
 
 
 
 15%), but little or no positive staining was observed
for CD8
 
 
 
 (Fig. 1 c). Therefore, CD1d tetramer positive T
cells in human peripheral blood can be divided into two
subsets: a CD4
 
 
 
 subset and a CD4
 
 
 
 subset that contains
cells expressing CD8
 
  
 
 homodimers, but almost none ex-
pressing CD8
 
  
 
 heterodimers.
We next examined expression of the NK complex re-
ceptors CD161, CD94, and CD69 by CD1d tetramer pos-
itive T cells. In C57Bl/6 mice, generally 
 
 
 
5% of splenic T
cells coexpress CD161, and 60–80% of these T cells are
stained by 
 
 
 
-GalCer loaded murine CD1d tetramers (13,
14). However, an analysis of CD161 staining of human pe-
ripheral blood lymphocytes found that 
 
 
 
25% of the T cells
from healthy adult donors coexpressed CD161 (42). We
found that a mean of 17 
 
 
 
 8.4% of the total peripheral
blood T cells from five healthy donors expressed CD161,
but only a small fraction stained positively with the 
 
 
 
-Gal-
Cer loaded human CD1d tetramer (Fig. 1 d). Most tet-
ramer positive T cells were positive for CD161 (mean
 
  
 
72 
 
 
 
 14%). In contrast, CD94 was expressed by a mean of
49 
 
 
 
 22% of the CD1d tetramer positive cells, and CD69
was detected on very few tetramer positive cells (mean
 
  
 
6.4 
 
 
 
 2.8%). Hence, our results show that most CD1d tet-
ramer positive T cells express CD161 but are not necessar-
ily positive for other NK complex markers, and the great
majority of human CD161
 
 
 
 T cells are not 
 
 
 
-GalCer spe-
cific CD1d-restricted T cells.
 
Cytokine Production by Fresh CD1d-restricted T Cells.
 
CD1d-restricted T cells were first noted for their ability to
rapidly secrete substantial amounts of the Th2 cytokine IL-4
upon anti-CD3 stimulation, but more recent investiga-
tions using 
 
 
 
-GalCer to selectively stimulate murine
CD1d-restricted T cells have observed Th1 biased cytokine
responses immediately after stimulation (43–46). Analysis of
cytokine production by in vitro cultured human CD1d-
restricted T cell clones has demonstrated that most clones
from healthy donors produce both IFN-
 
 
 
 and IL-4, but it
is unclear whether this is representative of the cytokine se-
cretion of CD1d-restricted T cells in vivo (21, 29). There-
fore, we performed intracellular cytokine staining to inves-
tigate cytokine production by CD1d-restricted T cells
freshly isolated from human peripheral blood.
PBMC samples were treated for 6 h with PMA and ion-
omycin or incubated overnight with 
 
 
 
-GalCer, or with no
stimulus, in culture medium containing monensin to block
exocytosis. The samples were then washed and stained with
Figure 1. Flow cytometric staining of fresh human PBMCs using CD1d-Fc tetramers and antibodies against cell surface markers. a, b, and d are com-
posite contour/dot plots, in which areas of infrequent events are shown as individual dots and higher density areas are shown as concentric probability
contours with each successive layer depicting an increased frequency of events. a and b show lymphocytes from a PBMC sample that was stained with
anti-CD3, and CD1d tetramers treated with DMSO or  -GalCer, respectively. c is a contour plot showing the CD4 and CD8  staining of  -GalCer–
loaded tetramer positive lymphocytes. d shows the CD161 and  -GalCer–loaded CD1d tetramer staining of CD3  lymphocytes. Numbers in boxed areas
of a and b, and in the corners of c and d show the percentage of events contained within the boxes or quadrants, respectively.629 Gumperz et al.
the   -GalCer–loaded CD1d tetramer and anti-CD3 or
anti-CD4, then fixed and permeabilized and stained with
antibodies to Th1 or Th2 cytokines, or isotype-matched
negative control antibodies. This protocol resulted in clear
positive staining by the anti-cytokine antibodies compared
with the isotype matched negative control antibodies for a
fraction of both the tetramer positive and tetramer negative
T cells in the PMA/ionomycin treated samples (Fig. 2 and
Table I). For the  -GalCer–treated samples, a fraction of
the tetramer positive cells stained positively for cytokines,
while the tetramer negative cells were equivalent to the
unstimulated control (Table I, and data not shown). Un-
stimulated samples gave little or no positive staining for any
of the cytokines (Table I, and data not shown).
Remarkably, there was a clear-cut difference in the cy-
tokines produced by the CD4  and CD4  tetramer posi-
tive subsets: the CD4  subset made both Th1 and Th2 cy-
tokines, whereas the CD4  subset overwhelmingly made
IFN-  and TNF-  (Fig. 2 and Table I). PMA/ionomycin
treatment was more efficient at inducing cytokine produc-
tion than was incubation with  -GalCer, but the difference
in cytokine production between the CD4  and CD4  sub-
sets was observed for both types of stimulation (Table I).
Hence, CD4 expression distinguishes two subsets of
Figure 2. Flow cytometric probability contour plots of CD1d tetramer positive lymphocytes stained for intracellular cytokines. The plots are gated on
the  -GalCer–loaded CD1d tetramer positive lymphocytes within a PBMC sample, and show staining with anti-CD4 on the y-axes, and antibodies to
the intracelluar cytokines shown (b-j), or a negative control (a), on the x-axes. Plots b-j show staining of a PBMC sample that was stimulated with PMA
and ionomycin in the presence of monensin. The negative control antibody staining (a) was performed on an unstimulated PBMC sample from the same
donor. Numbers in the corners indicate the percentage of the events contained within each quadrant.
Table I. Cytokine Production by CD14 Tetramer-stained T Cell Subsets
Stimulation Tetramer subset IFN-  TNF-  GM-CSF IL-2 IL-4 IL-5 IL-6 IL-10 IL-13
None CD4  2.7 (1.5) 2.3 (1.9) 1.7 (1.2) 1.7 (1.2) 3.2 (2.5) 0.9 (1.0) 3.1 (1.1) 1.6 (1.6) 2.6 (2.9)
CD4  0 (0) 0 (0) 0 (0) 0 (0) 0.7 (1.5) 0 (0) 0 (0) 0.3 (0.6) 0 (0)
PMA/iono CD4  92 (1.5) 87 (4.6) 48 (23) 54 (22) 36 (11) 19 (5.4) 23 (10) 22 (2.5) 22 (5.7)
CD4  91 (7.1) 72 (5.9) 18 (16) 11 (5.6) 9.4 (5.8) 0 (0) 0.6 (1.1) 0.3 (0.6) 0.3 (0.6)
 -GalCer CD4  45 (8.6) 32 (3.5) 12 (15) 13 (13) 16 (9.5) 10 (7.5) 9 (6.4) 10 (11) 12 (13)
CD4  35 (19) 25 (14) 0 (0) 0.7 (1.4) 3.1 (.9) 0 (0) 2.9 (3.8) 1.1 (2.3) 0 (0)
PMA/iono Negative 22 (13) 17 (11) 2.6 (1.8) 20 (8.9) 1.0 (0.8) 0.08 (0.11) 0.02 (0.03) 0.5 (0.4) 0.6 (0.3)
The percentage of CD4  and CD4  CD1d tetramer positive lymphocytes that produced intracellular cytokines after  -GalCer, PMA/ionomycin,
or no stimulation. For comparison, the percentage of CD1d tetramer negative T cells that produced intracellular cytokines after PMA/ionomycin
stimulation is also shown. The mean percentages of cells that stained positively are given first, with the standard deviations shown in parentheses. The
results are compiled from 2–4 independent analyses of PBMC samples from three to six healthy donors.630 Functionally Distinct Subsets of CD1d-restricted NKT Cells
CD1d-restricted T cells that have different patterns of cyto-
kine production.
These results support the hypothesis that CD1d-
restricted T cells overall are a potent cytokine producing
subpopulation, since compared with tetramer negative T
cells, a large percentage of the CD1d tetramer positive T
cells stained positively for each of the cytokines tested (Ta-
ble I). Surprisingly, we find that in healthy donors most
CD1d-restricted T cells produced Th1 cytokines, and only
a minority produced each of the Th2 cytokines analyzed.
Because each cytokine was tested separately in this analysis,
it is unclear whether the Th2 cytokines were all produced
by the same CD4  tetramer positive cells or by different
subsets. However, because only  8% of the CD4  tet-
ramer positive cells did not produce IFN- , and Th2 cyto-
kines were generally produced by at least 20% of the CD4 
tetramer positive cells, most of the CD4  tetramer positive
cells that stained positively for Th2 cytokines in our analysis
probably also produce IFN-  (see Table I). Thus, many
Th2 cytokine producing tetramer positive cells probably
have a Th0 cytokine production phenotype, rather than a
traditional Th2 phenotype.
Nevertheless, compared with tetramer negative T cells,
Th2 cytokine producing cells were unusually common in
the CD4  tetramer positive population (see Table I). Par-
ticularly for IL-5 and IL-6, tetramer negative T cells that
stained positively were extremely rare, and CD1d tetramer
positive cells made up a significant fraction of the total IL-5–
and IL-6–producing PBMC T cells (mean   13   7.1%
and 19   14%, respectively). Thus, while the tetramer pos-
itive population as a whole appeared biased toward Th1
cytokine production, CD1d-restricted T cells may be a
very important source of certain Th2 cytokines. Moreover,
if the CD4  and CD4  subsets can be differentially acti-
vated in vivo, the segregation of CD1d-restricted T cells
into these two subsets that have different cytokine secretion
profiles could explain how some CD1d-restricted T cell–
mediated responses appear strongly biased toward Th1 cy-
tokines, while in other cases Th2 responses are prominent.
Cytolytic Functions of CD1d-restricted T Cells. To inves-
tigate the cytotoxic potential of fresh peripheral blood
CD1d-restricted T cells, we performed intracellular stain-
ing for perforin on unstimulated PBMC samples from five
healthy donors. There was generally little or no positive
perforin staining of the CD4  tetramer positive subset
(mean   8.5% positive and Fig. 3 a, top quadrants). In con-
trast, the percentage of the CD4  tetramer positive subset
that stained positively for perforin varied substantially from
donor to donor (range   0–55%, mean   23%, and Fig. 3
a, bottom quadrants). Hence, most CD1d-restricted T cells
from unstimulated peripheral blood did not express per-
forin, but cells of the CD4  subset more frequently con-
tained perforin than the CD4  subset.
Several reports have indicated that exposure to IL-2, IL-
12, or  -GalCer may enhance cytotoxicity by cultured
CD1d-restricted NKT cells (47–50). To investigate the
effects of stimulation on effector functions of CD1d-
restricted T cells, we incubated PBMC samples overnight
with  -GalCer, IL-2, IL-12, or LPS which potently in-
duces secretion of inflammatory cytokines, or treated them
for 6 h with PMA and ionomycin. Treatment with  -Gal-
Cer, IL-2, IL-12, and PMA/ionomycin was performed in
the presence of monensin to prevent secretion of cytokines
or other factors that could secondarily affect the CD1d-
restricted T cells. LPS treatment was performed in the pres-
ence or absence of monensin, to compare effects resulting
from the inflammatory response induced by LPS, with di-
rect effects of LPS. After stimulation the PBMC samples
were stained with the  -GalCer–treated CD1d tetramer
Figure 3. Flow cytometric probability contour plots showing intracellu-
lar perforin and IFN-  staining of CD1d tetramer positive lymphocytes af-
ter stimulation. The plots are gated on  -GalCer–loaded CD1d tetramer
positive lymphocytes within a PBMC sample, after the following treat-
ments: no stimulation (a); IL-2 stimulation (b); PMA/ionomycin stimula-
tion (c); and  -GalCer stimulation (d). The left column shows perforin
staining, and the right shows IFN-  staining. The y-axes of all plots show
CD4 staining on a four decade log scale. Numbers in the corners indicate
the percentage of the events contained within each quadrant.631 Gumperz et al.
and anti-CD4, then fixed, permeabilized, and stained for
perforin or IFN-  expression.
IL-2, IL-12, and PMA/Ionomycin Stimulation. After IL-2
or IL-12 treatment, a large fraction of the CD4  CD1d
tetramer positive cells expressed perforin, but the CD4 
subset was still almost completely perforin negative (Fig. 3
b and Fig. 4 a). Hence, exposure to IL-2 or IL-12 alone is
sufficient to upregulate perforin for much of the CD4 ,
but not the CD4  CD1d-restricted subset. In contrast,
PMA and ionomycin stimulation reproducibly induced a
fraction of the CD4  tetramer positive cells to express per-
forin, but did not enhance perforin staining in the CD4 
subset (Fig. 3 c and Fig. 4 a). Thus, perforin expression is
induced by different stimuli in CD1d-restricted T cells of
the CD4  and CD4  subsets. CD1d-restricted T cells of
the two subsets may therefore carry out cytolytic functions
in response to different signals in vivo.
LPS Stimulation. Interestingly, treatment of the PBMC
samples with LPS in the absence of monensin provided suf-
ficient stimulation for CD1d-restricted T cells of both the
CD4  and CD4  subsets to up-regulate perforin expression
(Fig. 4 a). However, perforin staining was not clearly en-
hanced by incubation with LPS in the presence of monensin
(Fig. 4 a). Therefore, the effect of LPS may be due to ex-
pression of soluble and/or cell surface molecules that depend
on intracellular transport. These results show that inflamma-
tory conditions, including exposure to LPS which is an early
indicator of gram negative bacterial infection, may prime a
fraction of CD1d-restricted T cells for cytolytic function.
Antigenic Stimulation. Unexpectedly, TCR stimulation
by antigen led to a qualitatively different outcome than
stimulation by cytokines or LPS. Treatment of PBMC
samples with  -GalCer in the presence of monensin did
not result in significantly increased numbers of perforin-
positive CD1d tetramer positive cells (Figs. 3 d and 4 a).
However, such  -GalCer treatment did induce IFN- 
production in both CD4  and CD4  tetramer positive
cells (Fig. 3 h and Fig. 4 b). Remarkably, in contrast to
their effects on perforin, IL-2, IL-12, and LPS completely
failed to induce IFN-  production in either subset of
CD1d tetramer positive cells (Fig. 3 f and Fig. 4 b). Thus,
exposure to a lipid antigen resulted in IFN-  production,
but did not lead to up-regulation of intracellular perforin,
whereas exposure to IL-2, IL-12, or LPS enhanced per-
forin staining, but did not induce IFN-  production.
This result contrasts with two reports that found in-
creased cytotoxicity or granzyme B expression in V 24 
NKT cells cultured with  -GalCer (47, 48). However, in
these studies the V 24  NKT cells were cultured with
monocytes or monocyte-derived dendritic cells and treated
with  -GalCer in the absence of monensin. In a murine
model, NKT cells induced monocyte-derived cells to se-
crete IL-12 after addition of  -GalCer (49). Hence, culture
of CD1d-restricted T cells with  -GalCer and myeloid
cells could result in secondary stimulation of cytotoxicity
by IL-12 or other factors.
Overnight incubation of the PBMC samples with
 -GalCer in the absence of monensin resulted in a dra-
matic ( 80%) reduction in the number of CD1d tetramer
positive cells detected compared with unstimulated sam-
ples (data not shown). This effect resembles the disap-
pearance of CD1d-restricted T cells in vivo upon adminis-
tration of  -GalCer that has been observed in a murine
system (14). Incubation of the PBMC samples with IL-2,
IL-12, LPS, or PMA and ionomycin did not lead to a sig-
nificant reduction in the number of CD1d tetramer posi-
tive cells detected. Moreover, when incubation of PBMC
samples with  -GalCer was performed in the presence of
monensin the number of CD1d tetramer positive cells was
generally 80–100% of the number detected in unstimu-
lated control samples. Hence, the disappearance of CD1d
tetramer positive cells was specific to  -GalCer stimula-
tion and depended on intracellular transport, suggesting it
may result from secretion or cell surface expression of as
yet unidentified factors.
Cytokine Receptor Expression. To assess whether the lack
of perforin up-regulation in response to IL-12 and IL-2 in
the CD4  CD1d-restricted T cell subset could be due to
the absence of appropriate cytokine receptors, we evaluated
expression of the IL-12 and IL-2 receptors by tetramer pos-
itive cells. The IL-12 receptor  1 chain was detected on
cells of both the CD4  and CD4  CD1d tetramer positive
subsets (mean   61   6.8% and 57   27% positive, re-
spectively). Similarly, IL-2 receptor expression was de-
tected on cells of both CD1d tetramer positive subsets, but
expression of the intermediate- and high-affinity forms dif-
fered between the CD4  and CD4  subsets. The IL-2 re-
Figure 4. Mean percentages of CD1d tetramer positive cells staining
positively for perforin and IFN-  after stimulation. Plot a shows perforin
staining, plot b shows IFN-  staining, after stimulation as shown on the
y-axis at the left. Gray bars show CD4  and stippled bars show CD4 
CD1d tetramer positive cells. Results are from six independent experi-
ments on three healthy donors.632 Functionally Distinct Subsets of CD1d-restricted NKT Cells
ceptor   chain (CD25) was expressed by 26   1.3% of the
CD4  tetramer positive cells, but by very few of the CD4 
cells (mean   7.0    7.3%), while the IL-2 receptor  
chain (CD122) was detected on a mean of 74   8.2% of
the CD4- tetramer positive cells, and on 59   28% of the
CD4  cells. Hence, a fraction of the CD4  CD1d tetramer
positive cells expressed the high affinity IL-2 receptor
(CD25 CD122), whereas most CD4  CD1d-restricted T
cells expressed the intermediate affinity IL-2 receptor
(CD122). Nonetheless, the lack of perforin expression in
response to IL-12 and IL-2 by CD4  tetramer positive cells
was not simply due to an absence of the cytokine receptors,
underscoring the finding that expression of intracellular
perforin appears to be regulated differently in the CD4 
and CD4  CD1d-restricted T cell subsets.
Expression of Receptors Associated with Cell Killing.
NKG2d is a lectin encoded in the NK complex that is ex-
pressed by NK cells,    T cells, and CD8     T cells, that
mediates or costimulates cytolysis of virally and bacterially
infected or neoplastic cells that express certain stress-
induced antigens (51–54). We investigated CD1d-restricted
T cell expression of cell surface NKG2d by two color flow
cytometric analysis. As a directly conjugated anti-NKG2d
antibody was not available, we compared PBMC samples
depleted of CD4  cells to CD4 undepleted samples to
evaluate whether NKG2d expression was biased toward
CD4  or CD4  CD1d-restricted T cells. In PBMC sam-
ples that were not depleted of CD4  cells, approximately
half of the CD1d tetramer positive cells stained positively
for NKG2d (Fig. 5 a, top panel). In PBMC samples that
were CD4 depleted, the fraction of CD1d tetramer-posi-
tive cells that were NKG2d-positive was increased (Fig. 5
a, bottom panel), suggesting that the CD4  CD1d-restricted
T cell subset is enriched for NKG2d expression compared
with the CD4  subset.
Taken together with our finding that exposure to IL-2,
IL-12, or LPS results in enhanced perforin expression, this
observation suggests CD4  CD1d-restricted T cells could
play a previously unrecognized role in microbial infec-
tions. Exposure to inflammatory conditions may serve to
activate the cytotoxic functions of CD4  CD1d-restricted
T cells, and NKG2d expression could permit cytolysis of a
broad range of virally or bacterially infected cells. More-
over, this observation could provide insight into the role of
CD1d-restricted T cells in tumor rejection. CD1d-restricted
T cells are required for the rejection of murine metastatic
tumors induced by pharmacological administration of
IL-12 or  -GalCer, and also appear to be involved in
elimination of tumors mediated by endogenous IL-12 se-
cretion (25, 55, 56). Paradoxically, however, tumor rejec-
tion is not blocked by antibodies to CD1d (55). Our
results indicate IL-12–activated CD4  CD1d-restricted T
cells could recognize tumor cells via engagement of
NKG2d rather than the TCR, and that cytolysis could
thus be CD1d-independent.
Cytotoxicity mediated by NKT cells has also been asso-
ciated with Fas/Fas ligand interactions (57). We investi-
gated FasL (CD95L) expression by CD1d-restricted T cells
after stimulation of PBMC samples with IL-2, IL-12,
 -GalCer, or PMA/ionomycin. Because CD95L is rapidly
cleaved from the cell surface by serum metalloproteinases
(58), we used intracellular staining to detect expression. In
unstimulated samples, there was little or no positive stain-
ing for CD95L among CD4  tetramer positive cells
(mean   1.9   3.4%), but slightly more positive staining
of the CD4  subset (mean   5.6   5.2%). (Fig. 5, top
panel). Treatment with  -GalCer, IL-2, or IL-12 did not
enhance CD95L staining for either subset (data not shown).
In contrast, after PMA/ionomycin stimulation a mean of
28   19% of the CD4  subset, and 7.5   8.1% of the CD4 
Figure 5. Flow cytometric probability contour plots
showing NKG2d and CD95L staining of CD1d tetramer
positive cells. The plots are gated on CD1d tetramer posi-
tive lymphocytes. a shows NKG2d staining of a sample
before depletion of CD4  cells (top panel), compared with
NKG2d staining after depletion of CD4  cells (bottom
panel). b shows CD4 staining compared with intracellular
staining for CD95L for an unstimulated sample (top
panel), and a PMA and ionomycin stimulated sample
(bottom panel).633 Gumperz et al.
subset, were positive for CD95L (see Fig. 5, bottom panel).
Hence, mainly CD4  CD1d-restricted T cells could be in-
duced to express CD95L, suggesting that regulatory func-
tions mediated by Fas/FasL interactions may be performed
mostly by the CD4  CD1d-restricted subset in vivo.
CD1d-restricted T Cell Homing Receptors. Elevated num-
bers of T cells expressing V 24/J Q TCRs have recently
been demonstrated in two inflammatory sites, chronic in-
flammatory demyelinating polyneuropathy lesions and pe-
riodontitis lesions, suggesting CD1d-restricted T cells may
migrate preferentially to areas of inflammation (59, 60). To
investigate the possible destinations of CD1d-restricted T
cells in peripheral blood, we stained for a series of homing
and chemokine receptors. In contrast to cytokine produc-
tion and perforin upregulation, chemokine and homing re-
ceptor expression did not correlate clearly with CD4 ex-
pression by CD1d tetramer positive cells (Table II). Most
tetramer positive cells were negative for CD62L and
CCR7, which are receptors involved in trafficking to
lymph nodes (Table II). A fraction of the CD1d tetramer
positive cells stained positively for the integrin  4 7, a
molecule that is expressed on effector cells that home to the
gut and associated lymphoid sites, and a fraction was posi-
tive for the CLA, which is associated with homing to skin
(Table II). The tetramer positive cells were almost com-
pletely negative for the integrin  E 7, which is expressed
by intraepithelial lymphocytes and a small percentage of
peripheral blood T cells (Table II). Two chemokine recep-
tors that are associated with Th1 responses and migration to
sites of inflammation, CCR5 and CXCR3, were expressed
by large percentages of CD1d tetramer positive cells (Table
II). Almost all tetramer positive cells stained positively for
CXCR4, a chemokine receptor that recognizes a broadly
distributed ligand, stromal cell–derived factor 1 . Hence,
most CD1d tetramer positive cells in peripheral blood had
a phenotype consistent with homing to peripheral tissues
and recruitment to sites of inflammation.
Conclusions. Our results emphasize that CD1d-
restricted T cells may be important cytolytic as well as cy-
tokine-producing effector cells that migrate to peripheral
sites of inflammation or immunological activity. A large
percentage of the CD4  CD1d tetramer positive cells ap-
peared to become primed for cytolytic function by expo-
sure to IL-2 and IL-12, and this subset was also primarily
oriented toward secretion of Th1 cytokines. Hence,
CD4  CD1d-restricted T cells had characteristics associ-
ated with activation of cell-mediated effector functions
and cytolysis, a profile resembling NK cells. Their up-reg-
ulation of perforin in response to inflammatory stimuli and
expression of NKG2d suggests CD4  CD1d-restricted T
cell may also resemble NK cells by performing cytolytic
effector functions in antibacterial, antiviral, and antitumor
immune responses.
In contrast, CD4  CD1d-restricted T cells may be more
oriented toward providing B cell help or immunoregula-
tory functions, as this subset accounted for almost all Th2
cytokine production by CD1d-restricted T cells, and could
be induced to express CD95L. Based on their potent Th2
cytokine production, CD4  CD1d-restricted T cells might
be predicted to be responsible for the protective effect of
NKT cells observed in autoimmune diabetes. An intriguing
further possibility, however, is that CD4  CD1d-restricted
T cells could play a pathogenic role in autoimmune disease
by mediating cytotoxicity in response to inflammatory
conditions, and/or by secreting Th1 cytokines in response
to self antigen recognition.
We also show that antigenic- and cytokine-mediated
stimulation can have profoundly different effects on CD1d-
restricted T cells, and that the CD4  and CD4  CD1d-
restricted T cell populations respond differently to these
stimuli. The principal APCs that have been found to ex-
press CD1d in humans are B cells and myeloid cells, in par-
ticular monocytes, macrophages, and dendritic cells (61,
62). Fresh B cells do not secrete IL-2 or IL-12, whereas
monocytes can produce IL-12, and activated T cells may
secrete IL-2 locally. Thus, our results suggest three poten-
tial functional outcomes for CD4  CD1d-restricted T cell
activation: (i) those that recognize antigens presented by
CD1d  B cells may become activated for cytokine secre-
tion but not cytotoxicity; (ii) those that receive antigenic
stimulation from monocytes could be primed for cytolysis
in addition to cytokine secretion; and (iii) exposure to IL-2,
IL-12, or inflammatory agents such as LPS, in the absence
of antigenic stimulation could lead to cytolytic activation
without cytokine production. Hence, in addition to recog-
nition of specific antigens, the type of APC and the local
cytokine environment are likely to be critical factors that
regulate the effector functions of CD1d-restricted T cells.
Table II. Chemokine and Homing Receptor Expression by CD1d Tetramer-stained T Cells
Tetramer subset CXCR3 CCR5 CXCR4 CCR7 CD62L  4 7  E 7 CLA
CD4  63 (16) 51 (19) 99 (0.6) 16 (10) 24 (20) 28 (17) 1 (0.6) 14 (8.6)
CD4  44 (13) 74 (17) 99 (1.7) 5.8 (8.0) 11 (8.3) 33 (29) 0 (0) 19 (16)
Negative 47 (12) 26 (14) NA NA 53 (17) 52 (11) 1.3 (0.6) 19 (6.3)
The percentage of CD4  and CD4  CD1d tetramer positive lymphocytes that stained positively for chemokine and homing receptors. For
comparison, the percentage of CD1d tetramer negative T cells staining positively for each marker is also shown. The mean percentages of cells that
stained positively are given first, with the standard deviations shown in parentheses. The results are compiled from three to five independent analyses
of four healthy donors.634 Functionally Distinct Subsets of CD1d-restricted NKT Cells
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